CG Oncology, Inc. SEC Filings

Director James J. Mulay completed option-related transactions on 10/09/2025. He exercised 5,903 stock options at an exercise price of $3.72 per share, then sold the resulting 5,903 shares at $43.99 per share pursuant to a Rule 10b5-1 trading plan adopted on 06/06/2025. After these transactions the reporting person beneficially owns 0 shares of common stock and retains derivative exposure showing 1,962 derivative securities reported as beneficially owned following the transactions. The reported stock option vests in 36 monthly installments beginning on 07/14/2023 and has an expiration date of 06/13/2033. The Form 4 was signed on 10/10/2025 by an attorney-in-fact.

Notice of Proposed Sale under Rule 144: An insider-related Form 144 for the issuer indicates a proposed sale of 6,557 common shares, valued at approximately $266,935.47, to be sold on 10/09/2025 on NASDAQ. The securities were acquired the same day via exercise of stock options and paid in cash. The filing also discloses multiple recent Rule 10b5-1 plan sales by the same account: 12,755 shares on 09/29/2025 for $499,886.31, 3,574 shares on 09/19/2025 for $139,350.26, 19,112 shares on 09/18/2025 for $745,627.92, and 27,015 shares on 09/05/2025 for $851,759.01. The filer certifies no undisclosed material adverse information and includes the standard attestation regarding Rule 10b5-1 trading plans.

Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions dated 09/30/2025. The filing shows a purchase/acquisition of 5,000 common shares and a simultaneous sale/disposition of 5,000 common shares sold under a Rule 10b5-1 trading plan at a weighted average price of $40.09. The reporter holds a fully vested director stock option with an exercise price of $0.60 covering 5,000 shares and reports total beneficial ownership of 119,077 shares following the transactions. The sale was effected under a 10b5-1 plan adopted on 09/06/2024.

Insider transactions by CG Oncology (CGON) director James J. Mulay on 09/29/2025: Mr. Mulay exercised 12,755 fully vested director stock options at an exercise price of $1.82 per share, converting them into 12,755 shares of common stock. On the same date those 12,755 shares were sold under a Rule 10b5-1 trading plan at a weighted average price of $39.19 per share (individual sale prices ranged from $38.99 to $39.41). Following the reported transactions, the reporting person holds no common shares but retains the director stock option record showing 12,755 underlying shares with an exercise price of $1.82 and an expiration of 07/18/2031. The Form 4 was signed by an attorney-in-fact.

CG Oncology, Inc. filing a Form 144 notifies the proposed sale of 5,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $195,400, to be sold on 09/30/2025 on NASDAQ. The shares were acquired the same day by exercise of stock options and paid in cash. The filer reports prior Rule 10b5-1 sales by Leonard E. Post totaling 4,000 shares in the past three months (2,000 sold on 07/17/2025 for $56,000; 1,000 on 09/03/2025 for $28,000; 1,000 on 09/15/2025 for $35,100). The filing shows 76,247,581 shares outstanding, so the proposed sale represents a de minimis fraction of outstanding shares.

James J. Mulay, a director of CG Oncology, Inc. (CGON), reported option exercises and immediate sales on September 18-19, 2025. On 09/18/2025 he exercised Director Stock Options to acquire 19,112 shares at an exercise price of $1.82 per share and, pursuant to a Rule 10b5-1 trading plan adopted June 6, 2025, sold those 19,112 shares at a weighted average price of $39.01. On 09/19/2025 he exercised an additional 3,574 options at $1.82 and sold those 3,574 shares at $38.99. The filing states the options were fully vested and the sales reduced the reported non-derivative beneficial ownership to zero following the transactions. The form is signed by an attorney-in-fact on behalf of Mr. Mulay.

Longitude-affiliated investors disclosed ownership in CG Oncology (CGON), holding a combined economic interest of 4,662,268 shares, representing 6.0% of the outstanding common stock based on 77,762,732 shares. Record owners include Longitude Venture Partners IV, L.P. (3,190,463 shares, 4.1%) and Longitude Prime Fund, L.P. (1,471,805 shares, 1.9%). The filing describes prior private purchases of preferred and common stock between 2022 and 2023 that converted into common stock upon the issuer’s IPO. The Reporting Persons say holdings are for general investment purposes, reserve the right to change their position, and note that a Longitude managing director serves on CG Oncology’s board. The filing references investor registration rights and disclaims current plans for any specific corporate actions.

Seven Fleet filed a Schedule 13D disclosing an open-market purchase of CG Oncology common stock. Seven Fleet Partners purchased 1,540,819 shares for approximately $49,999,983, including a tranche of 1,515,151 shares bought on September 11, 2025 at $33.00 per share under the issuer's at-the-market offering. The filing reports beneficial ownership of 1,515,151 shares (1.9%) by the reporting entities based on 77,762,732 shares outstanding; Dr. Brian Liu is shown with shared voting power and direct holdings equating to 2%. The Reporting Persons state they view the shares as undervalued and may buy or sell, engage with management, or consider other strategic actions.

CG Oncology, Inc. (CGON) filed a Form 144 reporting a proposed sale of 35,441 common shares with an aggregate market value of $1,336,834.52. The notice lists Morgan Stanley Smith Barney LLC as the broker and identifies the approximate sale date as 09/18/2025 on NASDAQ. The shares were recorded as acquired on 09/18/2025 through an exercise of stock options, paid in cash. The filing also discloses a prior Rule 10b5-1 sale by James J. Mulay of 27,015 shares on 09/05/2025 for gross proceeds of $851,759.01. The filer represents no undisclosed material adverse information.